Today we sit down (in person!) with Dr. Jeff Bien of Stanford University to break down all the details -- from the methods to the statistical analysis to the conclusions -- of the CheckMate 649 trial, which pitted first-line nivolumab plus chemotherapy against chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma.
